Support for Department of Defense Chemical Biological Defense medical countermeasures pre and post-exposure protection funding.
2025 · 1st Quarter (Jan 1 - Mar 31)
CMC PHARMACEUTICALS
Filed by CAPITOL COUNSEL LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2025
- Income
- $40,000.00
- Expenses
- Not reported
- Registrant
- CAPITOL COUNSEL LLC
- Client
- CMC PHARMACEUTICALS
- Filing UUID
- f51fbdf7-4abd-4d64-899d-a3caf687c07c
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to the FY26 National Defense Authorization Act and Defense Appropriations.
Support for Department of Defense Chemical Biological Defense medical countermeasures pre and post-exposure protection policy.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.